We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01766297
Recruitment Status : Recruiting
First Posted : January 11, 2013
Last Update Posted : April 4, 2023
Information provided by (Responsible Party):
Proton Collaborative Group

Brief Summary:

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy.

This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.

Condition or disease Intervention/treatment Phase
Breast Cancer Breast Neoplasm Breast Tumor Cancer of the Breast Radiation: Proton Radiotherapy Phase 2

Detailed Description:

Current standard of care for early stage breast cancer is mastectomy or breast conserving therapy with whole breast irradiation following lumpectomy. However, studies of breast cancer recurrence have demonstrated the majority of tumors to recur in or adjacent to the original tumor site. The question has thus been raised as to whether radiation to the whole breast is necessary or justified. Limiting radiation to the area of the original tumor may reduce acute and long-term skin and organ toxicities while making radiation therapy more convenient and less expensive. Several clinical trials are underway comparing partial breast irradiation (PBI) to whole breast irradiation. Numerous centers are offering partial breast irradiation outside of clinical trials as well, despite the lack of long-term safety and efficacy data on PBI.

Available PBI methods include brachytherapy, in which catheters or balloons are surgically inserted to deliver radiation therapy to the lumpectomy cavity, and conventional external beam radiation therapy, or EBRT. External beam photon therapy is attractive for its non-invasive nature and ability to deliver a more homogenous dose distribution compared to brachytherapy, however it also delivers a greater radiation dose to surrounding normal breast tissue.Proton therapy has the capacity to provide the same advantages as photon EBRT while minimizing dose to normal surrounding tissue. Clinical data on PBI with protons is minimal, however, leaving many questions unanswered. The impetus behind this protocol is to address these gaps by further investigating the feasibility, safety, and efficacy of proton therapy for partial breast irradiation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 132 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Study Start Date : February 2013
Estimated Primary Completion Date : January 2025
Estimated Study Completion Date : January 2033

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Proton Radiotherapy
Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
Radiation: Proton Radiotherapy

Primary Outcome Measures :
  1. To assess events of freedom from ipsilateral breast recurrence occurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor. [ Time Frame: At 3 years ]
    Freedom from failure (FFF): The events for FFF will be the first ipsilateral breast cancer recurrence. It is expected that less than 3% of patients will experience an ipsilateral breast cancer recurrence (FFF ≥ 97%). A recurrence rate of ≥ 10% (FFF ≤ 90%) is considered unacceptable. Therefore, the null hypothesis is the FFF of ipsilateral breast cancer recurrence is 90% or lower and the alternative hypothesis is that FFF of ipsilateral breast cancer is 97% or higher.

Secondary Outcome Measures :
  1. Assess number and severity of acute and long-term toxicity of partial breast irradiation using proton therapy for the treatment of early stage breast cancer. [ Time Frame: On average every 6 months for life ]
  2. To assess relationship between breast size and partial breast dosimetry. [ Time Frame: Average every 6 months for 3 years ]
  3. Determine quality of life results. [ Time Frame: Average every 6 months for 3 years ]
  4. To determine overall survival rate of patients with breast cancer treated with proton radiation. [ Time Frame: At 3 years ]
  5. To determine recurrence pattern of patients with breast cancer treated with proton partial breast irradiation. [ Time Frame: At 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must sign study-specific, IRB approved informed consent form prior to study entry. Note consent by legally authorized representative is not allowed for this trial.
  • Must be female.
  • Must be > = 50 years of age.
  • Must have a life expectancy of at least 5 years based on age and co-morbidities.
  • Must have pathology proven invasive ductal carcinoma (lobular is not allowed) and/or ductal carcinoma in situ (DCIS).
  • One of the following criteria must be met: (a) Tumors that are microscopically multifocal must be 3.0 cm or less in total aggregate size and encompassed within a single scar (b) Patient does not have microscopically multifocal tumor.
  • For tumors that are invasive, if in the presence of extensive intraductal component (EIC), the entire pathologic tumor size (including both the intraductal and invasive component) must be 3.0 cm or less.
  • Must be Stage 0, I, II (Tis, T1, or T2, N0, M0 per AJCC criteria 7th and/or 8th Ed.). If stage II, the tumor size must be < = 3.0 cm. A patient with invasive histology must have nodal stage pN0 by H&E stains on sentinel node biopsy or axillary lymph node dissection.
  • Must have ER positive disease with ER/PR report available.
  • For tumors that are invasive, HER2 must be performed (positive or negative is acceptable).
  • Must have a lumpectomy performed, with documented negative surgical margins by 0.2 cm or more. If re-excision results in negative surgical margins 0.2 cm or more, patient is eligible.
  • If image guidance with daily cone beam CT with direct physician visual assessment is used for treatment positioning, the presence of markers or clips in the surgical bed is recommended but not required. If cone beam CT imaging will NOT be used for image guidance, then the patient must be prepared to have 2 fiducial markers minimum, 3 preferred, placed prior to treatment (if not previously done).

    • If markers or clips were placed at the time of surgery, patient must be able to start treatment within 12 weeks after lumpectomy or re-excision for adequate margins.
    • If markers were not placed at the time of surgery and are needed, patient must have markers placed within 6 weeks after surgery.
    • If systemic chemotherapy was given, patient must have had clips or markers placed at the time of surgery (if they are needed) and patient must have simulation scans within 6 weeks of the completion of the chemotherapy.
  • Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy.

Exclusion Criteria:

  • Previous history of ipsilateral invasive breast cancer or DCIS.
  • Any clinical or radiographically suspicious nodes, unless biopsy proven benign.
  • Non-epithelial malignancies such as sarcoma or lymphoma.
  • Suspicious residual microcalcifications on mammography of either breast, unless negative for malignancy on pathology.
  • Multicentric or bilateral disease unless biopsy of the clinical abnormalities are performed and result is negative.
  • Lymphovascular space invasion (LVSI) on pathology specimen.
  • Any previously treated breast carcinoma or synchronous breast carcinoma in ipsilateral breast.
  • Prior radiation therapy to the ipsilateral breast or thorax.
  • Paget's disease of the nipple.
  • Histologic examination showing invasive lobular histology.
  • Skin involvement.
  • Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.
  • Significant infection or other co-existing medical condition that would preclude protocol therapy such as pregnancy, HIV/AIDS or collagen vascular diseases specifically systemic lupus erythematosus, scleroderma, or dermatomyositis.
  • Known BRCA 1 or BRCA 2 mutation.
  • Pregnant or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01766297

Layout table for location contacts
Contact: Matthew Morocco 630-836-8670 mmorocco@pcgresearch.org

Layout table for location information
United States, California
California Protons Cancer Therapy Center Recruiting
San Diego, California, United States, 92121
Contact: Alexandra Crawford, MPH    858-549-7431    alexandra.crawford@californiaprotons.com   
Principal Investigator: James Urbanic, MD         
United States, Illinois
Northwestern Medicine Chicago Proton Center Recruiting
Warrenville, Illinois, United States, 60555
Contact: Don Smith, MS, CCRC    630-933-7820    donald.smith3@nm.org   
Principal Investigator: Christy Kesslering, MD         
United States, Maryland
Maryland Proton Treatment Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Caitlin Eggleston    410-328-7586    caitlineggleston@umm.edu   
Principal Investigator: Elizabeth Nichols, MD         
United States, New York
New York Proton Center Recruiting
New York, New York, United States, 10035
Contact: Sidra Saeed, MS, ACRP-PM    212-994-9817    ssaeed@nyproton.com   
Principal Investigator: Isabelle Choi, MD         
United States, Oklahoma
Oklahoma Proton Center Recruiting
Oklahoma City, Oklahoma, United States, 73142
Contact: Jenny Washington, BSRT(T), CMD    405-773-6700    jenny.washington@okcproton.com   
Principal Investigator: John Chang, MD         
United States, Virginia
Inova Schar Cancer Institute Recruiting
Fairfax, Virginia, United States, 22031
Contact: Sangeetha Moturi    571-472-0343    sangeetha.moturi@inova.org   
Principal Investigator: Ashish Chawla, MD         
Hampton University Proton Therapy Institute Recruiting
Hampton, Virginia, United States, 23666
Contact: Donna Sternberg, RN, BSN, OCN    757-251-6839    Donna.sternberg@hamptonproton.org   
Principal Investigator: Christopher Sinesi, MD         
Sponsors and Collaborators
Proton Collaborative Group
Layout table for investigator information
Study Chair: Andrew Chang, MD Proton Collaborative Group
Layout table for additonal information
Responsible Party: Proton Collaborative Group
ClinicalTrials.gov Identifier: NCT01766297    
Other Study ID Numbers: BRE007-12
First Posted: January 11, 2013    Key Record Dates
Last Update Posted: April 4, 2023
Last Verified: April 2023
Keywords provided by Proton Collaborative Group:
Breast Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases